Full history for every metric is available with a Kvantra account
Alliance Pharma plc (APH.L)
Key financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 136 | 130 | 163 | 167 | 181 | 179 | 179 |
| Operating profit | £m | -8 | 28 | |||||
| Net profit | £m | 25 | 8 | 7 | -21 | -33 | -11 | -11 |
| EPS reported | £ | -0.02 | -0.02 | |||||
| Operating cashflow per share | £ | 0.07 | 0.07 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | 0.07 | 0.07 | |||||
| Free cash flow | £m | 38 | 29 | |||||
| Net debt | £m | 60 | 60 | |||||
| Book value equity | £m | 208 | 208 | |||||
| Book value per share | £ | 0.38 | 0.38 | |||||
| Number of shares | m | 540.48 | 540.57 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.19 | 1.68 | |||||
| P/S LTM | x | 1.38 | 1.96 | |||||
| P/FCF LTM | x | 6.53 | 12.00 | |||||
| EV/EBITDA LTM | x | 80.38 | 91.90 | |||||
| EV/Sales LTM | x | 1.74 | 2.29 | |||||
| Earnings Yield LTM | % | -4.34% | -3.07% | |||||
| FCF Yield | % | 15.32% | 8.33% | |||||
| Quality | ||||||||
| ROE | % | -5.17% | -5.04% | |||||
| ROIC | % | -1.80% | -1.80% | |||||
| Operating margin | % | -4.53% | -4.53% | |||||
| Gross margin | % | 61.11% | 61.11% | |||||
| FCF/Sales | % | 21.18% | 21.18% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -1.02% | -1.02% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | +23.32% | +23.32% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.40 | 0.30 | |||||
| Net Debt/EBITDA | x | 16.39 | 16.39 | |||||
| EBIT/Net interest | x | -0.94 | -0.94 | |||||
| Net debt/market cap | % | 24.31% | 17.19% | |||||
| Net debt/Equity | x | 0.29 | 0.29 | |||||
| Gross debt/equity | x | 0.46 | 0.46 | |||||
Company overview
Alliance Pharma plc is a pharmaceutical firm with an expansive global reach, conducting business across Europe, the Middle East, Africa, the Asia Pacific region, China, and the Americas. The company's core activities involve sourcing, promoting, and distributing a diverse array of consumer healthcare items and prescribed medications. It currently manages the marketing rights for approximately 80 different products within these categories. Additionally, its offerings extend to medical devices, dietary supplements, and cosmetic goods. Notable brands within its portfolio include Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen. Founded in 1996, Alliance Pharma plc maintains its corporate base in Chippenham, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Alliance Pharma plc (APH.L)
Alliance Pharma plc is a pharmaceutical firm with an expansive global reach, conducting business across Europe, the Middle East, Africa, the Asia Pacific region, China, and the Americas. The company's core activities involve sourcing, promoting, and distributing a diverse array of consumer healthcare items and prescribed medications. It currently manages the marketing rights for approximately 80 different products within these categories. Additionally, its offerings extend to medical devices, dietary supplements, and cosmetic goods. Notable brands within its portfolio include Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen. Founded in 1996, Alliance Pharma plc maintains its corporate base in Chippenham, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free